Potential Chinook Therapeutics, Inc. (NASDAQ:KDNY) shareholders may wish to note that the Independent Director, Dolca Thomas, recently bought US$212k worth of stock, paying US$21.22 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
See our latest analysis for Chinook Therapeutics
Chinook Therapeutics Insider Transactions Over The Last Year
Notably, that recent purchase by Dolca Thomas is the biggest insider purchase of Chinook Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$21.47. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Chinook Therapeutics insiders decided to buy shares at close to current prices.
Chinook Therapeutics insiders may have bought shares in the last year, but they didn't sell any. They paid about US$17.73 on average. It is certainly positive to see that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Chinook Therapeutics
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Chinook Therapeutics insiders own about US$25m worth of shares. That equates to 1.9% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Chinook Therapeutics Tell Us?
It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of Chinook Therapeutics we think they are probably pretty confident of a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. You'd be interested to know, that we found 2 warning signs for Chinook Therapeutics and we suggest you have a look.